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Abstract Today, there is evidence that the cAMP-dependent
kinases (PKA) are not the only intracellular receptors involved
in intracellular cAMP signalling in eukaryotes. Other cAMP-
binding proteins have been recently identi¢ed, including some
cyclic nucleotide-gated channels and Epac (exchange protein
directly activated by cAMP) proteins. All these proteins bind
cAMP through conserved cyclic nucleotide monophosphate-
binding domains. However, all putative cAMP-binding proteins
having such domains, as revealed by computer analysis, do not
necessarily bind cAMP, indicating that their presence is not a
su⁄cient criteria to predict cAMP-binding property for a pro-
tein.
' 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Cyclic AMP (cAMP)-dependent protein kinases do not
account for all e¡ects of cAMP in vertebrate cells
cAMP is a second messenger playing, in eukaryotes, a cru-
cial role in the intracellular signal transduction of various
stimuli controlling a wide variety of cellular events including
function, secretion, cell shape, cytoskeletal modelling, cell mi-
gration, proliferation, di¡erentiation, and apoptosis. Since the
seventies until a few years ago, it was believed that most if not
all the cAMP e¡ects were mediated by the activation of the
cAMP-dependent kinases (PKA). PKAs are present, in most
cells, as two types of isoenzymes, PKAI and PKAII, which
are tetramers composed of two catalytic (C) and two regula-
tory (RIK,L or RIIK,L) subunits [1]. Each R subunit has two
cAMP-binding domains (site A and site B). Upon binding of
two cAMP molecules on both R subunits, the inactive tet-
ramer is dissociated into one dimer of R subunits and two
active C subunits which then phosphorylate various cytoplas-
mic and nuclear target proteins. Later, some cyclic nucleotide-
gated (CNG) channels were found to be directly activated by
cAMP in some specialised cells like in olfactory neurones
where they play a role in the transduction of sensory signals
[2^4].
In 1997, we suggested that PKA-independent mechanisms
might be required in some cAMP-dependent e¡ects in thyroid
cells [5]. Indeed, the microinjection of active PKA was not
su⁄cient to induce cell proliferation or the expression of thy-
roglobulin, a thyroid-speci¢c gene, although it mimicked some
other cAMP-stimulated events such as thyroperoxidase ex-
pression and typical morphological changes. However, all
cAMP e¡ects required PKA activation showing that PKA
was necessary. Following our data, the involvement of
PKA-independent pathways has also been suggested in other
cAMP-mediated events in di¡erent cell types, for example, in
the glial ¢brillary acidic protein induction in glial cells [6], in
the mitogen-activated protein kinases activation in melano-
cytes [7], in the di¡erentiating action of FSH in granulosa
cells [8], in actin depolarisation in skeletal muscle cells [9],
and in the inhibition of interleukin-5 release by human T
lymphocytes [10]. These conclusions were mainly based on
the absence of inhibition of cAMP e¡ects by H89, a suppos-
edly speci¢c PKA inhibitor. Taken together, all these reports
suggested the existence and the importance of PKA-indepen-
dent pathways in the transduction of many cAMP-mediated
e¡ects, and thereby called into question the dogma consider-
ing PKA as the main intracellular receptor of cAMP in mam-
malian cells. Based on such ¢ndings, searches for other cAMP
e¡ectors were initiated by di¡erent groups. They were based
on Blast searches of proteins with a similitude to PKAs, ca-
tabolite gene activation proteins and CNG channels.
2. cAMP-binding proteins related to catabolite gene activator
protein (CAP)
In 1998, two novel cAMP receptors, Epac1 and Epac2 (ex-
change factor directly activated by cAMP, also called cAMP-
GEFI and cAMP-GEFII), were identi¢ed [11,12]. The Epac
proteins are guanine nucleotide exchange factors (GEFs)
which, upon cAMP binding, speci¢cally activate the small G
proteins Rap1 and Rap2 [13]. Epac1 and Epac2 have respec-
tively one and two cAMP-binding sites which are located in
the N-terminal part of the proteins. Epac1 is broadly ex-
pressed, whereas Epac2 is prominent in the brain and the
adrenal glands [12].
Along with the Escherichia coli CAP, all the cAMP-binding
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proteins known at that time shared a common cyclic nucleo-
tide monophosphate (cNMP)-binding domain. The structure
of CAP has been crystallised. According to the crystal struc-
ture of CAP, the cNMP-binding domain consists of a stretch
of 120 amino acids containing a ¢rst K-helix, an eight-
stranded anti-parallel L-barrel structure followed by two other
K-helices [14]. The cyclic nucleotide binding occurs in a pocket
formed by the K-helix C and L-barrel, where the remaining
invariant residues are located [15,16].
Based on sequence homology with the cNMP-binding do-
main of CNG-gated channels, a novel family of hyperpolar-
isation-activated cation channels (HAC1^3) expressed in brain
and heart has been later identi¢ed [17]. The cAMP binding
permits the channels to open more rapidly [18]. The possible
existence of other cAMP-binding proteins having such a CAP-
related cAMP-binding domain in eukaryotic cells is the ques-
tion we have addressed in this review.
3. Other new putative cAMP-binding proteins related to CAP
To identify new cAMP-binding protein coding sequences,
we performed an advanced TBLASTN search in the non-re-
dundant DNA sequence and expressed sequence tag (EST)
databases using the cNMP-binding domains of the proteins
known to bind cAMP as query sequences. These proteins were
the regulatory subunits RIK,L and RIIK,L of PKA, Epac1 and
2, the olfactory channel (CNG-2) and CAP of E. coli. The
output protein sequences unrelated to the queries were then
analysed by the pro¢le scan software available on the Expasy
web site (www.expasy.ch). Three sequences encoding proteins
containing one or several cNMP-binding motifs (PS50042)
were retrieved: the neuropathy target esterase (NTE, acces-
sion number: NM006702) which contains three putative
cAMP-binding sites, a mouse embryo EST sequence
(AI595216, Image 493605 cDNA clone) and the KIAA0313
human sequence (accession number: AB002311) provided
from brain cDNA sequencing [19]. The alignment of their
cNMP-binding motifs with the cAMP-binding domains of
the query sequences was performed with the MultiAlign bio-
informatic tool (Fig. 1). All these ¢ve putative cyclic nucleo-
tide-binding domains ¢t quite well with the consensus se-
quence determined from the CAP-related proteins. Most of
the conserved residues, located in the L-barrel, critical for
the structure of the cAMP-binding pocket or involved in the
cAMP interaction, were also found in the new putative
cAMP-binding domains. In KIAA0313 we found the
-G^GE^VI-G-V- and -G-FG- but not the PRAA/T motifs;
in AI595216 we found -G^GD^Y-A-V-G-I- and -FGE^
PRT^A^F-V- motifs ; in NTE we found -G^ (Q)GQ/D^
Y-V-G-(V)- in the three cNMP motifs of this protein; the
PRAT sequence was only found in the third domain. As
this motif was described to be involved in the interaction
with the cyclic nucleotide, we presumed that this third
cNMP-binding domain was the most likely to bind cAMP
as compared with the other two.
NTE is a large transmembrane protein with a serine ester-
ase activity which catalyses hydrolysis of lysophospholipids
[20,21]. It is abundantly expressed in neurones of the brain,
but also in a variety of non-neuronal tissues including intes-
tine, placenta, testis and kidney. NTE inhibition by organo-
phosphorus esters is responsible for the organophosphate-in-
duced delayed neuropathy characterised by a paralysis of the
lower limbs due to degeneration of long axons in the spinal
cord and in peripheral nerves. In Drosophila, its homolog, the
Swiss cheese (SWS) protein, is required for brain develop-
ment. The catalytic domain of NTE is located in the C-termi-
nal part of the protein; the N-terminal part, which contains
the three cNMP-binding domains, constituting a putative reg-
ulatory domain.
The Im493605 sequence encodes a 228 residues polypep-
tide; we renamed it Im49. This small protein contains only
one putative cNMP-binding site. Although this sequence was
isolated from a mouse embryonic library, a Blast search using
the Im49 clone sequence revealed only bacterial homologous
sequences. It was not found in any eukaryote genome. The
highest homology was found for a hypothetical protein from
Pseudomonas £uorescens (ZP00086400.1), showing 70% iden-
tity with Im49. Furthermore, Northern blotting or reverse
transcription-PCR reactions did not allow us to detect or
amplify this sequence using adult or embryonic mRNA as
material sources. These observations led us to conclude that
Im49 was probably not coded by the mouse genome but most
Fig. 1. Alignment of the cNMP-binding domains of new putative cAMP-binding proteins with those of the cAMP-binding proteins used as
queries in Blast searches. These are E. coli CAP (P03020), human RIK (P10644), RIL (P31321), RIIK (P13861) and RIIL (P31323), human
Epac1 (AF103905) and cAMP-GEFII (U78516) and human CNG-2 (Q16280). Regions of secondary structure in CAP sequence according to
its crystal structure are indicated at the top. Residues of high consensus value (80%) are coloured in black, residues of low consensus value
(40%) are coloured in grey.
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probably by a bacterial organism infecting the mouse or the
cDNA preparation during library construction.
KIAA0313 encodes the PDZ-GEF1 protein which was, at
the same time, identi¢ed as a new Rap-speci¢c GEF protein
[22]. This protein is clearly related to the Rap-GEF family: it
presents an overall similarity of 29% with Epac1, and homol-
ogy raises to 50% in the cNMP-binding and GEF domains.
However, unlike the Epac protein, PDZ-GEF1 was shown not
to bind cAMP and its Rap-GEF activity not to be regulated
by this second messenger [23]. It contains a PDZ domain, but
its mechanism of regulation is not yet elucidated.
4. Demonstration of cAMP binding: methods
Following sequence analysis, the next step was to verify, by
biochemical procedures, whether the putative cAMP-binding
proteins are really able to bind cAMP. A useful method,
which has often been used to detect the R subunits of PKA
in cell or tissue extracts, is the photolabelling with 8-azido-
[32P]cAMP. Pull down assays using cAMP-linked agarose
beads (N6- or C8-linked beads from Sigma) is another simply
method, which has been used by Kawazaki to demonstrate the
cAMP-binding property of the Epac proteins [12]. Both can
be performed using either in vitro translated proteins or pro-
teins expressed either in BL21 bacteria such as GST-tagged
proteins, or in COS cells such as myc- or His-tagged proteins.
In our hand, both methods worked beautifully with the RIK
subunit, but not convincingly with full length Epac. Obtaining
large amounts of recombinant protein from bacteria is di⁄-
cult for long transmembrane proteins, so for NTE, we decided
to express only shorter fragments containing either the ¢rst
cNMP-binding domain alone (NTE-d1), the second plus the
Fig. 2. cAMP-binding assay using small Microcon spin down ¢lters (Microcon YM-10 from Amicon). The sample (300 Wl), containing
[3H]cAMP and the puri¢ed protein, was applied on the top of the ¢lter. Filters were centrifuged so that the upper volume, in which the protein
was concentrated, was reduced 10-fold. cpm content of 20 Wl was counted before the centrifugation in the initial sample (start) and after centri-
fugation, in the upper fraction (top) and the £ow-through (FT). A: cAMP binding on puri¢ed His-tagged RIK (expressed in bacteria) using
bu¡er containing 0.1WM [3H]cAMP in the absence or with increasing amounts of unlabelled cAMP; B: binding on puri¢ed GST-tagged Im49
and GST-tagged NTE-d2 (containing the second and third cNMP-binding domains) using bu¡er containing 0.1, 0.3 or 1 WM [3H]cAMP; re-
sults were expressed in terms of the ratio of cpm counted at the end vs the initial cpm amount (icpm); competition of the binding was made
with 1 mM of unlabelled cAMP (+cold).
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third domains (NTE-d2), or all three domains (NTE-d3) fused
to GST. EpacvcA, deleted from its N-terminal part contain-
ing the cNMP-binding domain, and an irrelevant protein used
as negative controls were negative. However, no speci¢c
cAMP binding was observed with NTE (full length or
cNMP-containing domains) and Im49.
As we were unable to show binding of the 8-azido-cAMP
analog to full length Epac, one of our positive controls, any
conclusion could be drawn from the photolabelling experi-
ments. The inability of Epac to bind cAMP in the pull
down assays, using cAMP-agarose beads, does not agree
with previous data published by Kawazaki. This negative re-
sult may be explained by the fact that the interaction of
cAMP with Epac has been reported to be highly dynamic,
implying a rapid dissociation rate [24]. Therefore, this suggests
that the use of non-equilibrium methods may be not appro-
priate to detect cAMP binding on Epac. A suitable equilibri-
um cAMP-binding assay is the Hummel and Dreyer method
based on size-exclusion chromatography (Sephadex G-25) us-
ing [3H]cAMP-containing bu¡er for equilibration and elution.
This method worked very well in our hands with both RI
subunit and Epac. Because our new putative cAMP-binding
proteins NTE and Im49 might have a rapid dissociation rate,
we decided to test their cAMP-binding abilities with this
assay. However, our tested proteins, especially NTE, aggre-
gated and bound irreversibly on the Sephadex columns. Sev-
eral bu¡ers were tested, but no convincing results were ob-
tained.
We then developed a new method using small Microcon
spin down ¢lters (Microcon YM-10 from Amicon). The sam-
ple (300 Wl), containing [3H]cAMP and the puri¢ed protein, is
applied on top of the ¢lter. Filters are centrifuged so that the
upper volume, in which the protein is retained, is reduced 10-
fold. In the case of cAMP binding to the protein, the concen-
tration of the labelled nucleotide should increase in the upper
part of the ¢lter and decrease in the £ow-through. Inversely
concentrations should remain unchanged in the absence of
binding. By this method both puri¢ed Epac1 and RIK subunit
bound highly and speci¢cally cAMP. The binding was abol-
ished in the presence of unlabelled cyclic nucleotide (cAMP
1 mM) and was not observed with the bovine serum albumin
used as a negative control. In the absence of unlabelled car-
rier, the percentage of cAMP bound to RIK was estimated to
be around 81% (Fig. 2A). Consistent with the known a⁄nity
of the R subunit for cAMP, this percentage progressively
diminished in the presence of increasing concentrations of
unlabelled cAMP. Using this protocol, we have tested the
cAMP binding on puri¢ed Im49-GST and NTE-d3-GST pro-
teins. However, as shown in Fig. 2B, no cAMP binding to
these queried proteins has been observed, even for concentra-
tions of [3H]cAMP raising up to 1 WM (Dremier, unpublished
data).
5. Signi¢cance of algorithm-predicted cNMP-binding domains
Since the discovery of CNG channels and Epac proteins
and according to several studies, including our work in thy-
roid cells [5], reporting the involvement of PKA-independent
mechanisms in various cAMP-mediated e¡ects, it is now evi-
dent that PKAs are not the only intracellular cAMP receptors
playing a critical role in the transduction of the cAMP signal
in eukaryotes. Using a bioinformatics search, NTE, Im49 and
PDZ-GEF1 were identi¢ed as new putative cAMP-binding
proteins having a cNMP-binding site related to CAP.
For PDZ-GEF1, which was identi¢ed simultaneously by us
and several other groups, di¡erent contradictory data have
been published concerning its ability to bind cAMP [25^27].
Indeed, Pham et al. reported that CNrasGEF, a protein iden-
tical to PDZ-GEF1, was a cAMP-responsive GEF for the
small G protein Ras. However, a recent publication strongly
suggests that PDZ-GEF1 de¢nitely does not bind cAMP and
that cAMP does not regulate its GEF activity [23]. The same
conclusion has also been drawn for PDZ-GEF2, a new mem-
ber of this protein family.
For NTE and Im49, neither the 8-azido-[32P]cAMP photo-
labelling and cAMP-agarose pull down procedures, which
worked nicely with the R subunit (but not with Epac), nor
a new equilibrium cAMP-binding assay using small Microcon
spin down ¢lters, which worked with both Epac and R sub-
unit, allowed us to demonstrate that these proteins were able
to bind cAMP. Negative results could still be explained by the
use of a non-appropriate method or procedure, by an incor-
rect folding of the protein after puri¢cation, by an absence
of critical post-translational modi¢cation, or by requirement
of interactions with protein partners, membranes or lipids.
Nevertheless, consistent with our ¢ndings, it has recently
been reported that cAMP does not regulate the in vitro ester-
ase activity of NTE [21].
All these observations raise the question of the biochemical
signi¢cance of cNMP-related binding domains. One probable
explanation is that they result from biological evolution. We
may suggest that their ancestral proteins were able to bind
cAMP, but that this property has been lost with evolution.
It is also possible that these proteins bind another nucleotide
or another similar small molecule. Our observations indicate
that the presence of a predicted cNMP-binding domain iden-
ti¢ed by bioinformatics tools is clearly not a su⁄cient criteria
to predict a cAMP-binding property for a protein. By exten-
sion, we may assume that this is true for any predicted protein
domain, so that such kind of data should be carefully exam-
ined before drawing conclusions about their real functional
signi¢cance.
6. cAMP-binding proteins non-related to CAP
The possible existence of unknown cAR proteins remains
an intriguing question.
In addition to the cAMP-binding proteins related to CAP,
including R subunits of PKA, CNG channels and Epac pro-
teins, at least two other types of cyclic nucleotide-binding
proteins exist : the cyclic nucleotide phosphodiesterases
(PDE, reviewed in [28]) containing a catalytic cyclic nucleo-
tide-binding site and, for the PDE 2, 5, 6 isoforms, two addi-
tional non-catalytic cyclic nucleotide-binding sites named
GAF domains (cGMP-speci¢c and stimulated PDEs, Anabae-
na adenylate cyclases, and E. coli FhlA, [29]) and the plasma
membrane cARs of Dictyostelium playing critical roles in the
di¡erentiation of this organism [30].
The observation that, in response to stimuli, cAMP is ex-
ported out of various cell types including renal cells, adipo-
cytes, glial cells and cardiomyocytes suggests the existence of
cAMP exporter proteins and even extracellular cAMP recep-
tors in eukaryotes [31]. Identi¢cation of cAMP-binding pro-
teins related to PDEs or to Dictyostelium cARs should be
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attempted. Such proteins could be either identi¢ed by bioin-
formatics approaches, as we did with cAMP-binding proteins
related to CAP, or isolated from cell or tissue membrane
preparations by 8-azido-[32P]cAMP photolabelling, as it was
successfully done to isolate several cARs of Dictyostelium
[32,33].
Acknowledgements: S.D. is Scienti¢c Research Worker of the Fonds
National de la Recherche Scienti¢que. The work of our lab is sup-
ported by the Ministe're de la Politique Scienti¢que (PAI), the Fond
National de la Recherche Me¤dicale, the Te¤le¤vie and the Association
contre le cancer. We thank P. Glynn for the gift of the NTE cDNA
and F. Zwartkruis for the gift of plasmids encoding Epac.
References
[1] Doskeland, S.O., Maronde, E. and Gjertsen, B.T. (1993) Bio-
chim. Biophys. Acta 1178, 249^258.
[2] Dhallan, R.S., Yau, K.W., Schrader, K.A. and Reed, R.R.
(1990) Nature 347, 184^187.
[3] Nakamura, T. and Gold, G.H. (1987) Nature 325, 442^444.
[4] Goulding, E.H., Tibbs, G.R. and Siegelbaum, S.A. (1994) Nature
372, 369^374.
[5] Dremier, S., Pohl, V., Poteet-Smith, C., Roger, P.P., Corbin, J.,
Doskeland, S.O., Dumont, J.E. and Maenhaut, C. (1997) Mol.
Cell Biol. 17, 6717^6726.
[6] Anciaux, K., Van Dommelen, K., Nicolai, S., Van Mechelen, E.
and Slegers, H. (1997) J. Neurosci. Res. 48, 324^333.
[7] Busca, R., Abbe, P., Mantoux, F., Aberdam, E., Peyssonnaux,
C., Eychene, A., Ortonne, J.P. and Ballotti, R. (2000) EMBO J.
19, 2900^2910.
[8] Gonzalez-Robayna, I.J., Falender, A.E., Ochsner, S., Firestone,
G.L. and Richards, J.S. (2000) Mol. Endocrinol. 14, 1283^1300.
[9] Hirshman, C.A., Zhu, D., Panettieri, R.A. and Emala, C.W.
(2001) Am. J. Physiol. Cell Physiol. 281, C1468^C1476.
[10] Staples, K.J., Bergmann, M., Tomita, K., Houslay, M.D.,
McPhee, I., Barnes, P.J., Giembycz, M.A. and Newton, R.
(2001) J. Immunol. 167, 2074^2080.
[11] de Rooij, J., Zwartkruis, F.J., Verheijen, M.H., Cool, R.H., Nij-
man, S.M., Wittinghofer, A. and Bos, J.L. (1998) Nature 396,
474^477.
[12] Kawasaki, H., Springett, G.M., Mochizuki, N., Toki, S., Na-
kaya, M., Matsuda, M., Housman, D.E. and Graybiel, A.M.
(1998) Science 282, 2275^2279.
[13] de Rooij, J., Rehmann, H., van Triest, M., Cool, R.H., Wit-
tinghofer, A. and Bos, J.L. (2000) J. Biol. Chem. 275, 20829^
20836.
[14] Weber, I.T. and Steitz, T.A. (1987) J. Mol. Biol. 198, 311^326.
[15] Shabb, J.B. and Corbin, J.D. (1992) J. Biol. Chem. 267, 5723^
5726.
[16] Canaves, J.M. and Taylor, S.S. (2002) J. Mol. Evol. 54, 17^29.
[17] Ludwig, A., Zong, X., Jeglitsch, M., Hofmann, F. and Biel, M.
(1998) Nature 393, 587^591.
[18] Santoro, B. and Tibbs, G.R. (1999) Ann. N.Y. Acad. Sci. 868,
741^764.
[19] Nagase, T., Ishikawa, K., Nakajima, D., Ohira, M., Seki, N.,
Miyajima, N., Tanaka, A., Kotani, H., Nomura, N. and Ohara,
O. (1997) DNA Res. 4, 141^150.
[20] Glynn, P. (1999) Biochem. J. 344, 625^631.
[21] van Tienhoven, M., Atkins, J., Li, Y. and Glynn, P. (2002)
J. Biol. Chem. 277, 20942^20948.
[22] de Rooij, J., Boenink, N.M., van Triest, M., Cool, R.H., Wit-
tinghofer, A. and Bos, J.L. (1999) J. Biol. Chem. 274, 38125^
38130.
[23] Kuiperij, H.B., de Rooij, J., Rehmann, H., van Triest, M., Wit-
tinghofer, A., Bos, J.L. and Zwartkruis, F.J. (2003) Biochim.
Biophys. Acta 1593, 141^149.
[24] Kraemer, A., Rehmann, H.R., Cool, R.H., Theiss, C., de Rooij,
J., Bos, J.L. and Wittinghofer, A. (2001) J. Mol. Biol. 306, 1167^
1177.
[25] Liao, Y., Kariya, K., Hu, C.D., Shibatohge, M., Goshima, M.,
Okada, T., Watari, Y., Gao, X., Jin, T.G., Yamawaki-Kataoka,
Y. and Kataoka, T. (1999) J. Biol. Chem. 274, 37815^37820.
[26] Ohtsuka, T., Hata, Y., Ide, N., Yasuda, T., Inoue, E., Inoue, T.,
Mizoguchi, A. and Takai, Y. (1999) Biochem. Biophys. Res.
Commun. 265, 38^44.
[27] Pham, N., Cheglakov, I., Koch, C.A., de Hoog, C.L., Moran,
M.F. and Rotin, D. (2000) Curr. Biol. 10, 555^558.
[28] Conti, M. and Jin, S.L. (1999) Prog. Nucleic Acids Res. Mol.
Biol. 63, 1^38.
[29] Aravind, L. and Ponting, C.P. (1997) Trends Biochem. Sci. 22,
458^459.
[30] Johnson, R.L., Van Haastert, P.J., Kimmel, A.R., Saxe, C.L.,
Jastor¡, B. and Devreotes, P.N. (1992) J. Biol. Chem. 267,
4600^4607.
[31] Bankir, L., Ahloulay, M., Devreotes, P.N. and Parent, C.A.
(2002) Am. J. Physiol. Renal Physiol. 282, F376^F392.
[32] Theibert, A., Klein, P. and Devreotes, P.N. (1984) J. Biol. Chem.
259, 12318^12321.
[33] Klein, P.S., Sun, T.J., Saxe, C.L., Kimmel, A.R., Johnson, R.L.
and Devreotes, P.N. (1988) Science 241, 1467^1472.
FEBS 27348 12-6-03
S. Dremier et al./FEBS Letters 546 (2003) 103^107 107
